An Update of Safety and Efficacy Results oiii Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing Prior TKI Therapies

被引：3

作者：

Cortes, Jorge E. ^{[1
]}

Saikia, Tapan ^{[2
]}

Kim, Dong-Wook ^{[3
,4
]}

Alvarado, Yesid ^{[5
]}

Nicolini, Franck E. ^{[6
]}

Rathnam, Krishnakumar ^{[7
]}

Khattry, Navin ^{[8
]}

Apperley, Jane F. ^{[9
]}

Deininger, Michael W. ^{[10
]}

de Lavallade, Hugues ^{[11
]}

Charbonnier, Aude ^{[12
]}

Granacher, Nikki ^{[13
]}

Gambacorti-Passerini, Carlo ^{[14
]}

Lucchesi, Alessandro ^{[15
]}

Mauro, Michael J. ^{[16
]}

Vandenberghe, Peter ^{[17
]}

Verhoef, Gregor ^{[17
]}

Whiteley, Andrew R. ^{[18
]}

Nag, Arijit ^{[19
]}

Radhakrishnan, Vivek S. ^{[19
]}

Apte, Shashikant ^{[20
]}

Yao, Siu-Long ^{[21
]}

Inamdar, Sandeep ^{[22
]}

Sreenivasan, Jayasree ^{[22
]}

Dillu, Ruchika Irene ^{[22
]}

Chimote, Geetanjali ^{[22
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[2] Prince Aly Khan Hosp, Mumbai, Maharashtra, India

[3] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med,Dept Hematol, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Ctr Leon Berard, Hematol Dept, Lyon, France

[7] Meenakshi Mission Hosp & Res Ctr, Lake Area, Melur Main Rd, Madurai, Tamil Nadu, India

[8] Tata Mem Hosp, ACTREC, Dept Med Oncol, BMT Unit, Navi Mumbai, India

[9] Imperial Coll, Hammersmith Hosp, Ctr Haematol, Dept Med, London, England

[10] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[11] Kings Coll Hosp London, NHS Fdn Trust, Dept Haematol Med, London, England

[12] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[13] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

[14] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

[15] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, FC, Italy

[16] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[17] UZ Leuven, Dept Hematol, Leuven, Belgium

[18] Baylor Univ, Med Ctr, Dallas, TX USA

[19] Tata Med Ctr, Clin Hematol Oncol & HCT, Kolkata, India

[20] Punes Sahyadri Hosp, Pune, Maharashtra, India

[21] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[22] Sun Pharma Adv Res Co Ltd, Mumbai, Maharashtra, India

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

309

引用

页数：6

共 50 条

[21] ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
Sasaki, Koji
Mauro, Michael
Levy, Moshe Yair
Atallah, Ehab L.
Koller, Paul B.
Maegawa, Rodrigo
Damon, Andrea
Kumar, Julie
Khan, Mahmudul
Cortes, Jorge E.
BLOOD, 2022, 140 : 6784 - 6786
[22] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
Kantarjian, HM
Cortes, J
O'Brien, S
Giles, F
Albitar, M
Rios, MB
Shan, J
Faderl, S
Garcia-Manero, G
Issa, JP
Thomas, D
Capdeville, R
Talpaz, M
BLOOD, 2001, 98 (11) : 260B - 260B
[23] Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)
Vannuffel, Pascal
Bavaro, Luana
Nollet, Friedel
Aynaci, Asena
Martelli, Margherita
Devos, Helena
De Rop, Celine
Soverini, Simona
BLOOD, 2019, 134
[24] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Matloub, Yousif
Gore, Lia
Loh, Mignon L.
Pui, Chin-Hon
Hanley, Michael J.
Lu, Vickie
Leonard, E. Jane
Granier, Muriel
Biondi, Andrea
Silverman, Lewis B.
BLOOD, 2020, 136
[25] ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
Atallah, Ehab L.
Mauro, Michael J.
Sasaki, Koji
Levy, Moshe Y.
Koller, Paul B.
Sadek, Islam
Yang, Daisy
Ruckel-Kumar, Julie
Khan, Mahmudul H.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: Update of a phase I study.
Sawyers, CL
Kantarjian, H
Shah, N
Cortes, J
Paquette, R
Donato, N
Nicoll, J
Bleickardt, E
Chen, TT
Talpaz, M
BLOOD, 2005, 106 (11) : 16A - 16A
[27] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in Imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL).
Kantarjian, HM
Ottman, O
Cortes, J
Wassman, M
Wunderle, L
Bhalla, K
Jones, D
Hochhaus, A
Rae, P
Alland, L
Dugan, M
Albitar, M
Giles, F
BLOOD, 2005, 106 (11) : 15A - 16A
[28] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL)
Kantarjian, HM
Ottmann, O
Hochhaus, A
Mueller, M
Cortes, J
Wassmann, B
Wunderle, L
Bhalla, K
Jones, D
Rafferty, T
Albitar, M
Rae, L
Dugan, M
Alland, L
Giles, F
ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
[29] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Hughes, Timothy
Mauro, Michael
Kim, Dong-Wook
Cortes, Jorge
Rea, Delphine
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel
Hochhaus, Andreas
Goh, Yeow-Tee
le Coutre, Philipp
Lang, Fabian
Cacciatore, Silvia
Aimone, Paola
Stenson, Laura
Polydoros, Fotis
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
[30] A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
Jiang, Qian
Li, Zongru
Qin, Ya-Zhen
Zhao, Ting
Liu, Bingcheng
Chen, Zi
Niu, Qian
Men, Lichuang
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Huang, Xiao-Jun
BLOOD, 2022, 140

← 1 2 3 4 5 →